In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 385-388

  Anastasiou, Diane M ^a   Thorne, Grace M ^a   Luperchio, Steven A ^a   Alder, Jeff D ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Daptomycin; Linezolid; Quinupristin dalfopristin; Reduced susceptibility

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIA; HUMANS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; VIRGINIAMYCIN;

EID: 33750378919     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.017     Document Type: Review

References (17)

1. Alborn W.E., Allen N.E., and Preston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 35 (1991) 2282-2287
2. Allen N.E., Alborn W.E., and Hobbs J.N. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 35 (1991) 2639-2642
3. Canepari P., Boaretti M., Del Mar Lleo M., and Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 34 (1990) 1220-1226
4. Barry A.L., Fuchs P.C., and Brown S.D. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45 (2001) 1919-1922
5. Moellering R.C. Introduction: Problems with antimicrobial resistance in gram positive enterococci. Clin Infect Dis 26 (1998) 1177-1178
6. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
7. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
8. Duncan RA, Haas S, Craven D, et al. Linezolid-resistant vancomycin-resistant Enterococcus faecium infection in a liver transplant recipient intolerant of quinupristin/dalfopristin and treated with daptomycin. In: Abstracts of the 39th (2001) Infectious Diseases Society of America (IDSA) Meeting; 2001 October 25-28; San Francisco, CA (Abstract 537).
9. Silverman J.A., Oliver N., Andrew T., and Li T.C. Resistance studies with daptomycin. Antimicrob Agents Chemother 45 (2001) 1799-1802
10. Critchley IA, Draghi DC, Le H, et al. Activity of daptomycin against gram-positive pathogens resistant to linezolid and quinupristin-dalfopristin: 2000-2002 data from SECURE-Net. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2002 September 27-30; San Diego, CA (Abstract C-1448).
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Thirteenth informational supplement. M100-S13 (2003), NCCLS, Villanova, PA
12. Snydman D.R., Jacobus N.V., McDermott L.A., Lonks J.R., and Boyce J.M. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 44 (2000) 3447-3450
13. Fluit A.C., Schmitz F.J., Verhoef J., and Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antmicrob Agents Chemother 48 (2004) 1007-1011
14. Zurenko GE, Todd WM, Hafkin B, Meyers B, Kauffman C, Bock J, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1999 September 26-29; San Francisco, CA (Abstract 848).
15. Herrero I.A., Issa N.C., and Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346 (2002) 867-869
16. National Nosocomial Infections Surveillance (NNIS) System Report. Data Summary from January 1992-June 2001, issued August 2001. Am J Infect Control 29 (2001) 404-421
17. Wilson P., Andrews J.A., Charlesworth R., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51 (2003) 186-188